|

Xembify Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Immune Globulin Subcutaneous (Human), 20% (IGSC 20%)

Pipeline

Phase 3: 1

Top Sponsors

  • Grifols Therapeutics LLC1

Indications

  • Multiple Myleoma1
  • Bacterial Infections1
  • Hypogammaglobulinemia1
  • B-Cell Chronic Lymphocytic Leukemia1
  • Non-hodgkin Lymphoma1

St. Petersburg, Florida1 trial

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

GC2202 Study Site 103

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.